|
1
|
de Bont JM, Packer RJ, Michiels EM, den
Boer ML and Pieters R: Biological background of pediatric
medulloblastoma and ependymoma: a review from a translational
research perspective. Neuro Oncol. 10:1040–1060. 2008.PubMed/NCBI
|
|
2
|
Lin J, Zheng Y, Chen K, Huang Z, Wu X and
Zhang N: Inhibition of FOXM1 by thiostrepton sensitizes
medulloblastoma to the effects of chemotherapy. Oncol Rep.
30:1739–1744. 2013.PubMed/NCBI
|
|
3
|
Maheshwari RK, Singh AK, Gaddipati J and
Srimal RC: Multiple biological activities of curcumin: a short
review. Life Sci. 78:2081–2087. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anand P, Sundaram C, Jhurani S,
Kunnumakkara AB and Aggarwal BB: Curcumin and cancer: an ‘old-age’
disease with an ‘age-old’ solution. Cancer Lett. 267:133–164.
2008.
|
|
5
|
Kunnumakkara AB, Anand P and Aggarwal BB:
Curcumin inhibits proliferation, invasion, angiogenesis and
metastasis of different cancers through interaction with multiple
cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar
|
|
6
|
Dorai T, Cao YC, Dorai B, Buttyan R and
Katz AE: Therapeutic potential of curcumin in human prostate
cancer. III Curcumin inhibits proliferation, induces apoptosis, and
inhibits angiogenesis of LNCaP prostate cancer cells in vivo.
Prostate. 47:293–303. 2001. View Article : Google Scholar
|
|
7
|
Gilbertson RJ and Ellison DW: The origins
of medulloblastoma subtypes. Annu Rev Pathol. 3:341–365. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guessous F, Li Y and Abounader R:
Signaling pathways in medulloblastoma. J Cell Physiol. 217:577–583.
2008. View Article : Google Scholar
|
|
9
|
Angers S and Moon RT: Proximal events in
Wnt signal transduction. Nat Rev Mol Cell Biol. 10:468–477.
2009.PubMed/NCBI
|
|
10
|
Roussel MF and Hatten ME: Cerebellum
development and medulloblastoma. Curr Top Dev Biol. 94:235–282.
2011.
|
|
11
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Northcott PA, Korshunov A, Witt H,
Hielscher T, Eberhar CG, Mack S, Bouffet E, Clifford SC, Hawkins
CE, French P, Rutka JT, Pfister S and Taylor MD: Medulloblastoma
comprises four distinct molecular variants. J Clin Oncol.
29:1408–1414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thompson MC, Fuller C, Hogg TL, Dalton J,
Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM,
Kellie SJ, Taylor MD, Curran T, Gajjar A and Gilbertson RJ:
Genomics identifies medulloblastoma subgroups that are enriched for
specific genetic alterations. J Clin Oncol. 24:1924–1931. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koch A, Hrychyk A, Hartmann W, Waha A,
Mikeska T, Schuller U, Sorensen N, Berthold F, Goodyer CG, Wiestler
OD, Birchmeier W, Behrens J and Pietsch T: Mutations of the Wnt
antagonist AXIN2 (Conductin) result in TCF-dependent transcription
in medulloblastomas. Int J Cancer. 121:284–291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun P, Liu Y, Ying H and Li S: Action of
db-cAMP on the bystander effect and chemosensitivity through
connexin 43 and Bcl-2-mediated pathways in medulloblastoma cells.
Oncol Rep. 28:969–976. 2012.PubMed/NCBI
|
|
16
|
Wang X, Shi Q, Xu K, Gao C, Chen C, Li XL,
Wang GR, Tian C, Han J and Dong XP: Familial CJD associated PrP
mutants within transmembrane region induced Ctm-PrP retention in ER
and triggered apoptosis by ER stress in SH-SY5Y cells. PLoS One.
6:e146022011. View Article : Google Scholar
|
|
17
|
Goel A, Kunnumakkara AB and Aggarwal BB:
Curcumin as ‘Curecumin’: from kitchen to clinic. Biochem Pharmacol.
75:787–809. 2008.
|
|
18
|
Cole GM, Teter B and Frautschy SA:
Neuroprotective effects of curcumin. Adv Exp Med Biol. 595:197–212.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Perry MC, Demeule M, Regina A, Moumdjian R
and Beliveau R: Curcumin inhibits tumor growth and angiogenesis in
glioblastoma xenografts. Mol Nutr Food Res. 54:1192–1201.
2010.PubMed/NCBI
|
|
20
|
Elamin MH, Shinwari Z, Hendrayani SF,
Al-Hindi H, Al-Shail E, Khafaga Y, Al-Kofide A and Aboussekhra A:
Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers
apoptosis in medulloblastoma cells. Mol Carcinog. 49:302–314.
2010.PubMed/NCBI
|
|
21
|
Lee SJ, Krauthauser C, Maduskuie V,
Fawcett PT, Olson JM and Rajasekaran SA: Curcumin-induced HDAC
inhibition and attenuation of medulloblastoma growth in
vitro and in vivo. BMC Cancer. 11:1442011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baryawno N, Sveinbjornsson B, Kogner P and
Johnsen JI: Medulloblastoma: a disease with disorganized
developmental signaling cascades. Cell Cycle. 9:2548–2554. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rogers HA, Miller S, Lowe J, Brundler MA,
Coyle B and Grundy RG: An investigation of WNT pathway activation
and association with survival in central nervous system primitive
neuroectodermal tumours (CNS PNET). Br J Cancer. 100:1292–1302.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baryawno N, Sveinbjornsson B, Eksborg S,
Chen CS, Kogner P and Johnsen JI: Small-molecule inhibitors of
phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/β-catenin
pathway cross-talk and suppress medulloblastoma growth. Cancer Res.
70:266–276. 2010.PubMed/NCBI
|
|
25
|
Rogers HA, Sousa S, Salto C, Arenas E,
Coyle B and Grundy RG: WNT/β-catenin pathway activation in Myc
immortalised cerebellar progenitor cells inhibits neuronal
differentiation and generates tumours resembling medulloblastoma.
Br J Cancer. 107:1144–1152. 2012.
|
|
26
|
Cimmino F, Scoppettuolo MN, Carotenuto M,
De Antonellis P, Dato VD, De Vita G and Zollo M: Norcantharidin
impairs medulloblastoma growth by inhibition of Wnt/β-catenin
signaling. J Neurooncol. 106:59–70. 2012.PubMed/NCBI
|
|
27
|
Sundram V, Chauhan SC, Ebeling M and Jaggi
M: Curcumin attenuates β-catenin signaling in prostate cancer cells
through activation of protein kinase D1. PLoS One.
7:e353682012.
|
|
28
|
Frame S, Cohen P and Biondi RM: A common
phosphate binding site explains the unique substrate specificity of
GSK3 and its inactivation by phosphorylation. Mol Cell.
7:1321–1327. 2001. View Article : Google Scholar
|
|
29
|
Mao Y, Ge X, Frank CL, Madison JM, Koehler
AN, Doud MK, Tassa C, Berry EM, Soda T, Singh KK, Biechele T,
Petryshen TL, Moon RT, Haggarty SJ and Tsai LH: Disrupted in
schizophrenia 1 regulates neuronal progenitor proliferation via
modulation of GSK3β/β-catenin signaling. Cell. 136:1017–1031.
2009.PubMed/NCBI
|
|
30
|
Wu G, Huang H, Garcia Abreu J and He X:
Inhibition of GSK3 phosphorylation of β-catenin via phosphorylated
PPPSPXS motifs of Wnt coreceptor LRP6. PLoS One. 4:e49262009.
|
|
31
|
Raffel C: Medulloblastoma: molecular
genetics and animal models. Neoplasia. 6:310–322. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jozwiak J, Grajkowska W and Wlodarski P:
Pathogenesis of medulloblastoma and current treatment outlook. Med
Res Rev. 27:869–890. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao X, Song T, He Z, Tang L and Zhu Y: A
novel role of cyclinD1 and p16 in clinical pathology and prognosis
of childhood medulloblastoma. Med Oncol. 27:985–991. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mimeault M and Batra SK: Frequent
deregulations in the hedgehog signaling network and cross-talks
with the epidermal growth factor receptor pathway involved in
cancer progression and targeted therapies. Pharmacol Rev.
62:497–524. 2010. View Article : Google Scholar
|
|
35
|
Guoand X and Wang XF: Signaling cross-talk
between TGF-β/BMP and other pathways. Cell Res. 19:71–88. 2009.
|
|
36
|
Li C, Zhang Y, Lu Y, Cui Z, Yu M, Zhang S
and Xue X: Evidence of the cross talk between Wnt and Notch
signaling pathways in non-small-cell lung cancer (NSCLC):
Notch3-siRNA weakens the effect of LiCl on the cell cycle of NSCLC
cell lines. J Cancer Res Clin Oncol. 137:771–778. 2011. View Article : Google Scholar : PubMed/NCBI
|
